Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 389-400

  Rustum, Y M ^a   Harstrick, A ^a   Cao, S ^a   Vanhoefer, U ^a   Yin, M B ^a   Wilke, H ^a   Seeber, S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 5 ETHYNYLURACIL; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METESIND GLUCURONATE; METHOTREXATE; NOLATREXED; PEMETREXED; PRODRUG; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 0031014682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.389     Document Type: Review

References (77)

1. Pinedo HM, Peters GJ: 5-Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
4. O'Connell MJ: A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5-FU) for the treatment of advanced colorectal cancer: Experience of the Mayo Clinic and North Central Cancer Treatment Group, in Rustum Y, McGuire JJ (eds): The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy: Advances in Experimental Medicine and Biology. New York, NY, Plenum, 1988, pp 173-182
5. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
6. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
7. Mansoni S: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-949, 1995
8. Peters GJ, Van Groeningen CJ: Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469-480, 1991
9. Moran RG: Leucovorin enhancement of the effects of the fluoropyrimidines on thymidilate synthase. Cancer 63:1008-1012, 1989
10. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871-881, 1995
11. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 36:407, 1995 (abstr)
12. Cao S, Frank C, Shirasaka T, et al: 5-Fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1:839-845, 1995
13. Spears CP, Gustavsson BG, Verne M, et al: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48:5894-5900, 1988
14. Jackman AL, Taylor GA, O'Connor BM, et al: Activity of the thymidylate synthase inhibitor 2-desamino-N 10-propargy-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210in vivo. Cancer Res 50:5212-5218, 1990
15. Jackman AL, Taylor GA, Gibson W, et al: ICI tomudex, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586, 1991
16. Gibson W, Bisset GMF, Marsham PR, et al: The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI tomudex, in mouse and human cultured cells. Biochem Pharmacol 45:863-869, 1993
17. Taylor E, Kuhnt D, Shih C, et al: A dideazatetrahydrotolate analogue lacking a chiral center at C-6,n-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimidin-5-yl) ethyl] benzoyl-1-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454, 1992
18. Duch DS, Banks S, Dev IK, et al: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810-818, 1993
19. Ferone R, Hanlon MH, Waters KA, et al: Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89. Proc Am Assoc Cancer Res 34:274, 1993 (abstr)
20. Humphreys J, Smith G, Waters K, et al: Antitumour activity of the novel thymidylate synthase inhibitor 1843U89 in cells resistant to antifolates by multiple mechanisms. Proc Am Assoc Cancer Res 34:273, 1993 (abstr)
21. Webber SE, Bleckman TM, Attard J, et al: Design of thymidylate synthase inhibitors using protein crystal structures: The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36:733-746, 1993
22. Vaney MD, Marzoni GP, Palmer CL, et al: Crystal-structure-based design and synthesis of benz(cd)indole-containing inhibitors of thymidylate synthase. J Med Chem 35:663-676, 1992
23. Webber S, Bartlett CA, Boritzki TJ, et al: AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo pre-clinical studies. Cancer Chemother Pharmacol 37:509-517, 1996
24. O'Connor BM, Webber S, Jackson RC, et al: Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother Pharmacol 34:225-229, 1994
25. Clendennin NJ, Peterkin JJ, Webber S, et al: AG331, a "non-classical", lipophilic thymidylate synthase inhibitor for the treatment of solid tumours. Ann Oncol 5:133, 1994 (abstr) (suppl 5)
26. Rinaldi DA, Burris HA, Dorr FA, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY 231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995
27. Rafi I, Boddy AV, Taylor GA, et al: A phase I clinical study of the novel antifolate AG 337 given by 5 day oral administration. Ann Oncol 7:86, 1996 (abstr) (suppl 1)
28. Jodrell D, Bowman A, Rye R, et al: A clinical phase I pharmacokinetic and pharmcodynamic study of the lipophilic thymidylate synthase inhibitor AG337 administered by 10 day oral administration. Ann Oncol 7:86, 1996 (abstr) (suppl 1)
29. Rafi I, Taylor GA, Calveta JA, et al: Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) given by continuous intravenous infusion. Clin Cancer Res 1:1275-1284, 1995
30. Clendenin NJ, Collin MA, Johnston AL, et al: Thymitag (AG337): A novel thymidylate synthase inhibitor with clinical activity in solid tumors. Proc Am Assoc Cancer Res 37:171, 1996 (abstr)
31. Giantonio B, Qian M, Gallo J, et al: Phase I trial of AG331 as a 5-day continuous infusion. Proc Am Soc Clin Oncol 14:480, 1995 (abstr)
32. Jackman AL, Kelland LR, Kimbell R, et al: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (tomudex) in one mouse and three human cell lines. Br J Cancer 71:914-924, 1995
33. Smith SG, Lehman NL, Moran RG: Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 53:5697-5706, 1993
34. Yin MB, Guimares MA, Zhang ZZ, et al: Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res 52:5900-5905, 1992
35. Keyomarsi K, Samet J, Molnar G, et al: The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 268:15142-15149, 1993
36. Pressacco J, Mitrovski B, Erlichman C, et al: Effects of thymidylate inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55:1505-1508, 1995
37. Panadero A, Yin MB, Voigt W, et al: Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, tomudex and AG331. Oncol Res 7:73-81, 1995
38. Johnston PG, Behan KA, Allegra CJ, et al: ZD1694 (tomudex) resistant cell lines with markedly elevated thymidylate synthase levels. J Natl Cancer Inst 87:1558-1559, 1995
39. Lu K, Yin MB, McGuire JJ, et al: Mechanisms of resistance to N-[5-[N-(3, 4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L- glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem Pharmacol 50:391-398, 1995
40. Takamura Y, Kobayashi H, Gibson W, et al: The influence of drug-exposure conditions on the development of resistance to metholrexate or ZD1694 in cultured human leukaemia cells. Int J Cancer 66:29-36, 1996
41. Stephens TC, Calvete JA, Jones D, et al: Antitumor activity of new thymidylate synthase inhibitor D1694. Proc Am Assoc Cancer Res 31:342, 1990 (abstr)
42. Stephens TC, Valaccia BE, Sheader JL, et al: The thymidylate synthase inhibitor ICI tomudex is superior to CB3717, 5-fluorouracil and methotrexate against a panel of human tumour xenografts. Proc Am Assoc Cancer Res 32:328, 1991 (abstr)
43. Chang YM, Zielinski Z, Izzo J, et al: Pretreatment of colon carcinoma cells to D1694 (tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc Am Assoc Cancer Res 35:330, 1994 (abstr)
44. Harstrick A, Gonzales A, Hoffmann A, et al: Development and characterisation of human gastric, colon and breast carcinoma cell lines resistant to 5-FU using various, clinically relevant application schedules. Proc Am Assoc Cancer Res 36:317, 1995 (abstr)
45. Izzo J, Zielinski Z, Chang YM, et al: Molecular mechanisms of the synergistic sequential administration of D1694 followed by FUra in colon carcinoma cells. Proc Am Assoc Cancer Res 36:318, 1995 (abstr)
46. Van der Wilt CL, Pinedo HM, Kuiper CM, et al: Biochemical basis for the combined antiproliferative effect of AG337 or tomudex and 5-fluorouracil. Proc Am Assoc Cancer Res 36:379, 1995 (abstr)
47. Clarke S, Ward J, Planting A, et al: Phase I trial of ICI D1694, a novel thymidylate synthase inhibitor. Proc Am Assoc Cancer Res 33:406, 1992 (abstr)
48. Judson IR, Clarke S, Ward J, et al: Pharmacokinetics of ICI D1694 following a 15 minute infusion in patients with advanced cancer. Proc Am Soc Clin Oncol 11:117, 1992 (abstr)
49. Sorensen JM, Jordan E, Grem JL, et al: Phase I trial of ZD1694 (tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 5:132, 1994 (abstr) (suppl 5)
50. Zalcberg JR, Cunningham D, Van Cutsem E, et al: ZD1694, a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716-721, 1996
51. Smith IE, Spielmann M, Bonneterre J, et al: Tomudex (ZD1694), a new thymidylate synthase inhibitor with antitumor activity in breast cancer. Ann Oncol 5:132, 1994 (abstr) (suppl 5)
52. Bums H III, Van Hoff D, Bonen K, et al: A phase II trial of tomudex, a novel thymidylate synthase inhibitor in patients with advanced non small cell lung cancer. Ann Oncol 5:133, 1994 (abstr) (suppl 5)
53. Gore M, Earl H, Cassidy J, et al: Phase II study of tomudex (ZD 1694) in refractory ovarian cancer. Ann Oncol 5:133, 1994 (abstr) (suppl 5)
54. Pazdur R, Casper EG, Meropol NJ, et al: Phase II trial of tomudex (ZD 1694), a thymidylate synthase inhibitor, in advanced pancreatic cancer. Proc Am Soc Clin Oncol 13:207, 1994 (abstr)
55. Zeneca Pharmaceuticals: Data base on tomudex. Macclesfield, United Kingdom, Zeneca Pharmaceuticals, 1994
56. Cunningham D, Zalcberg JR, Rath U, et al: 'Tomudex' (ZD 1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A:1945-1954, 1995
57. Heggie D, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206, 1987
58. Coustere C, Mentre F, Sommadossi JP, et al: A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 28:123-129, 1991
59. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency in dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51, 1988
60. Diasio RB, Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12:2239-2242, 1994
61. Milano G, Etienne MC, Renée N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
62. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A:1517-1522, 1994
63. Milano G, Fischel JL, Etienne MCv et al: Inhibition of dihydropyrimidine dehydrogenase by α-interferon: Experimental data on human tumor cell lines. Cancer Chemother Pharmacol 34:147-152, 1994
64. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
65. Fischel JL, Etienne MC, Spector T, et al: Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 7:991-996, 1995
66. Porter DJT, Chestnut WGv Merril BM, et al: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267:5236-5242, 1992
67. Spector T, Harrington JA, Porter DJT: 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
68. Baccanari DP, Davis ST, Knick VC, et al: 5-Ethynyluracil: Effects on the pharmacokinetics and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci 90:11064-11068, 1993
69. Cao S, Rustum YM, Specter T: 5-Ethynyluracil modulation of the efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
70. Spector T, Porter DJTv Nelson D, et al: 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 19:565-571, 1994
71. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1988
72. Cao S, Frank C, Rustum YM: Role of fluoropyrimidine schedule and (6RvS) leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 88:430-436, 1996
73. Cao S, Baccanari DP, Joyner SS, et al: 5-Ethynyluracil (776C85):Effect on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res 55:6227-6230, 1995
74. Pazdur R, Lasseve Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen of metastatic colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994
75. Cao S, Shirasaka T, Rustum YM: Therapeutic selectivity of S-1, a new oral formulation of ftorafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and oxonic acid (Oxo) in rats bearing advanced colorectal carcinoma. Proc Am Assoc Cancer Res 36:290, 1995 (abstr)
76. Cao S, Shirasaka T, Rustum YM: Simultaneous inhibition of phosphoribosyl pyrophosphate simultaneous inhibition of phosphoribosyl pyrophosphate transferase and dihydropyrimidine dehydrogenase enhances the therapeutic selectivity of tegafur, a fluorouracil prodrug, alone and in combination with cisplatin. Proc Am Assoc Cancer Res 37:288, 1996 (abstr)
77. Taguchi T, Shirasaka T: New oral anticancer agent: S1. Ann Oncol 7:66, 1996 (abstr) (suppl 7)